Piper Sandler Companies (NYSE:PIPR) Releases Earnings Results, Beats Estimates By $0.81 EPS

Piper Sandler Companies (NYSE:PIPR) issued its quarterly earnings data on Friday. The financial services provider reported $4.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.99 by $0.81, Zacks reports. Piper Sandler Companies had a return on equity of 16.06% and a net margin of 10.84%. During the same quarter in the prior year, the business posted $4.03 earnings per share.

Piper Sandler Companies Price Performance

Shares of Piper Sandler Companies stock opened at $317.62 on Friday. The stock has a market capitalization of $5.65 billion, a price-to-earnings ratio of 33.93 and a beta of 1.46. The business has a 50-day moving average of $301.34 and a 200 day moving average of $313.16. Piper Sandler Companies has a 12 month low of $171.70 and a 12 month high of $351.80.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PIPR shares. The Goldman Sachs Group cut shares of Piper Sandler Companies from a “buy” rating to a “neutral” rating and set a $317.00 price target for the company. in a research report on Monday, January 6th. StockNews.com downgraded shares of Piper Sandler Companies from a “buy” rating to a “hold” rating in a report on Tuesday, January 7th.

Piper Sandler Companies Company Profile

Piper Sandler Companies operates as an investment bank and institutional securities firm that serves corporations, private equity groups, public entities, non-profit entities, and institutional investors in the United States and internationally. It offers investment banking services and institutional sales, trading, and research services for various equity and fixed income products; advisory services, such as mergers and acquisitions, equity and debt private placements, and debt and restructuring advisory; raises capital through equity and debt financings; underwrites municipal issuances; and municipal financial advisory and loan placement services, as well as various over-the-counter derivative products.